Search

Your search keyword '"González-Lama Y"' showing total 191 results
Start Over Author "González-Lama Y"
191 results on '"González-Lama Y"'

1. Consenso Delphi sobre Estrategias Terapéuticas y de Prevención Sanitaria de la hipovitaminosis D

Author

Aguilar del Rey J, Jódar Gimeno E, Brañas F, Gómez Alonso C, González Lama Y, Malouf-Sierra J, Sánchez Borrego R, Segura de la Morena J, Suárez Pérez JA, and Valdés y Llorca C

Subjects
consenso delphi, suplementación vitamina d, vitamina d, hipovitaminosis d, acciones esqueléticas y extraesqueléticas, Medicine, Osteopathy, RZ301-397.5
Abstract

Antecedentes: La elevada prevalencia de hipovitaminosis D en España es considerada una verdadera epidemia con importantes implicaciones para la salud por las múltiples funciones que ejerce la vitamina D tanto a nivel esquelético como extraesquelético. Para que las personas con insuficiencia o deficiencia en vitamina D alcancen los niveles séricos más adecuados, deben recibir suplementos de vitamina D. Este estudio se realizó con la finalidad de evaluar si en la práctica clínica habitual, el manejo de la hipovitaminosis D era llevada a cabo según las recomendaciones internacionales establecidas por las sociedades científicas. Métodos: Se realizaron dos rondas de circulación de un cuestionario Delphi entre un panel formado por médicos prescriptores habituales de vitamina D. Resultados: En general, los médicos del panel reconocieron la alta prevalencia de la hipovitaminosis D en España, la necesidad del cribado en los distintos grupos de riesgo y los beneficios de la suplementación en los pacientes con insuficiencia o déficit de vitamina D. Sin embargo, no se alcanzó el consenso en algunas de las aseveraciones relacionadas con los métodos de cuantificación de la vitamina D o con las recomendaciones para el manejo de la hipovitaminosis D. Conclusiones: La ausencia de acuerdo para algunos de los ítems reveló la necesidad de realizar acciones formativas destinadas a proporcionar un conocimiento adecuado y actualizado sobre las evidencias científicas y las recomendaciones para la práctica clínica de la suplementación de vitamina D.

Published
2022
Full Text
View/download PDF

2. DOP60 Prevalence of undiagnosed inflammatory Bowel Disease in patients with spondyloarthritis: EISER Study

Author

Gutiérrez Casbas, A, primary, Rodríguez-Lago, I, additional, Marín-Jiménez, I, additional, Plaza, Z, additional, Gratacós, J, additional, Trujillo, E, additional, Pérez-Pampín, E, additional, Barreiro de Acosta, M, additional, Aznar-Esquivel, A, additional, Carrillo, M, additional, García-Vivar, M L, additional, Muñoz-Villafranca, M D C, additional, Ladehesa, L, additional, Iglesias-Flores, E, additional, Merino, C, additional, González-Lama, Y, additional, Arévalo, M, additional, Calvet, X, additional, Brandy-García, A, additional, Izquierdo-Romero, M, additional, Manrique, S, additional, Olmedo, R, additional, García-LLorente, J F, additional, Zugaza, J, additional, Ros-Vilamajo, I, additional, Rull, N, additional, Pinto-Tasende, J A, additional, Ucha, P, additional, González, C, additional, Rodríguez-Martín, F, additional, Serrano, S, additional, Domínguez-Alvaro, M, additional, Prado-Galbarro, F J, additional, and Sanz, J, additional

Published
2024
Full Text
View/download PDF

10. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

Author

Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, Gisbert JP, Mesonero F, Benítez O, Taxonera C, Ponferrada-Díaz Á, Piqueras M, Lucendo AJ, Caballol B, Mañosa M, Martínez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Manceñido N, Martínez-Pérez T, López A, Rodríguez-Gutiérrez C, García-López S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de-Acosta M, Sicilia B, Barrio J, Pérez JL, Busquets D, Pérez-Martínez I, Navarro-Llavat M, Hernández V, Argüelles-Arias F, Ramírez Esteso F, Meijide S, Ramos L, Gomollón F, Muñoz F, Suris G, de Zarate JO, Huguet JM, Llaó J, García-Sepulcre MF, Sierra M, Durà M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutiérrez A, Varela P, Rull N, Gilabert P, Hernández-Camba A, Brotons A, Ginard D, Sesé E, Carpio D, Aceituno M, Cabriada JL, González-Lama Y, Jiménez L, Chaparro M, López-San Román A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastián S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galán H, Pajares R, Olcina P, Manzano P, Domènech E, Esteve M, On Behalf Of The Eneida Registry Of Geteccu, [Zabana Y] Hospital Universitari Mútua Terrassa, Terrassa, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Marín-Jiménez I] Hospital Gregorio Marañón, Madrid, Spain. [Rodríguez-Lago I] Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain. Biocruces Bizkaia Health Research Institute, Galdakao, Spain. [Vera I] Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Martín-Arranz MD] Hospital Universitario La Paz, Madrid, Spain. [Guerra I] Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Instituto de Investigación Hospital Universitario La Paz (IdiPaz), Madrid, Spain. [Piqueras M, Mena R] Servei de Digestologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain, Consorci Sanitari de Terrassa, and Universidad de Sevilla. Departamento de Medicina

Subjects
index, Pronòstic mèdic, Risk factors in diseases, COVID-19 (Malaltia), Article, Inflammatory bowel disease, Comorbiditat, inflammatory bowel disease, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity [PUBLIC HEALTH], Factors de risc en les malalties, SARS-CoV-2, COVID-19, determinants, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, Prognosis, enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades intestinales::enfermedad inflamatoria intestinal [ENFERMEDADES], infection, epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad [SALUD PÚBLICA], Medicine, Digestive System Diseases::Gastrointestinal Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [DISEASES], Intestins - Inflamació
Abstract

We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged >= 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having >= 2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD. This study is funded by the Carlos III Health Institute (COV20/00227: Co-IP Dra. Maria Esteve and Dra. Yamile Zabana), FEDER (Fondo Europeo de Desarrollo Regional) and supported by GETECCU. The ENEIDA Registry of GETECCU is supported by Takeda, Pfizer, Galapagos, AbbVie and Biogen.

Published
2022

12. P263 Influence of Crohn′s Disease phenotype in the retention rate of ustekinumab treatment: SUSTAIN Study

Author

Chaparro, M, primary, Bastón Rey, I, additional, Fernández-Salgado, E, additional, González García, J, additional, Ramos, L, additional, Diz-Lois Palomares, M T, additional, Argüelles, F, additional, Iglesias Flores, E, additional, Cabelo, M, additional, Rubio Iturria, S, additional, Núñez Ortiz, A, additional, Charro, M, additional, Ginard, D, additional, Dueñas Sadornil, C, additional, Merino Ochoa, O, additional, David, B, additional, Iyo, E, additional, Gutiérrez Casbas, A, additional, Ramírez de la Piscina, P, additional, Boscá-Watts, M M, additional, Arroyo, M, additional, García, M J, additional, Hinojosa, E, additional, Gordillo, J, additional, Martínez Montiel, P, additional, Velayos Jiménez, B, additional, Quílez Ivorra, C, additional, Vázque morón, J M, additional, Huguet, J M, additional, González Lama, Y, additional, Muñagorri Santos, A I, additional, Amo, V M, additional, Martín Arranz, M D, additional, Bermejo, F, additional, Martínez Cadilla, J, additional, Fradejas Salazar, P, additional, Novella, C, additional, Vispo, E, additional, Barreiro-de Acosta, M, additional, and Gisbert, J P, additional

Published
2021
Full Text
View/download PDF

13. P509 Influence of concomitant immunosuppresives in retention rate in Crohn′s Disease patients under ustekinumab in the SUSTAIN Study

Author

Chaparro, M, primary, Bastón Rey, I, additional, Fernández-Salgado, E, additional, González García, J, additional, Ramos, L, additional, Diz-Lois Palomares, M T, additional, Argüelles, F, additional, Iglesias Flores, E, additional, Cabello, M, additional, Rubio Iturria, S, additional, Núñez Ortiz, A, additional, Charro, M, additional, Ginard, D, additional, Dueñas Sadornil, C, additional, Merino Ochoa, O, additional, Busquets, D, additional, Iyo, E, additional, Gutiérrez Casbas, A, additional, Ramírez de la Piscina, P, additional, Boscá-Watts, M M, additional, Arroyo, M, additional, García, M J, additional, Hinojosa, E, additional, Gordillo, J, additional, Martínez Montiel, P, additional, Velayos Jiménez, B, additional, Quílez Ivorra, C, additional, Vázquez Morón, J M, additional, Huguet, J M, additional, González Lama, Y, additional, Muñagorri Santos, A I, additional, Amo, V M, additional, Martín Arranz, M D, additional, Bermejo, F, additional, Martínez Cadilla, J, additional, Fradejas Salazar, P, additional, Novella, C, additional, Vispo, E, additional, Barreiro-de Acosta, M, additional, and Gisbert, J P, additional

Published
2021
Full Text
View/download PDF

14. Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU

Author

Zabana Abdo, Y, primary, Marín-Jiménez, I, additional, Rodríguez-Lago, I, additional, Ramírez Esteso, F, additional, Meijilde, S, additional, Ramos, L, additional, Gomollón, F, additional, Muñoz, F, additional, Suris, G, additional, Ortiz de Zárate, J, additional, Huguet, J M, additional, Llaó, J, additional, García-Sepulcre, M, additional, Sierra, M, additional, Durà, M, additional, Estrecha, S, additional, Fuentes Coronel, A, additional, Hinojosa, E, additional, Olivan, L, additional, Iglesias, E, additional, Gutiérrez, A, additional, Varela, P, additional, Rull, N, additional, Gilabert, P, additional, Hernández-Camba, A, additional, Brotons, A, additional, Ginard, D, additional, Sesé, E, additional, Carpio, D, additional, Aceituno, M, additional, Cabriada, J L, additional, González-Lama, Y, additional, Jiménez, L, additional, Chaparro, M, additional, López-San Román, A, additional, Alba, C, additional, Plaza-Santos, R, additional, Piqueras, M, additional, Domènech, E, additional, and Esteve, M, additional

Published
2021
Full Text
View/download PDF

19. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients

Author

González-Lama, Y., Bermejo, F., López-Sanromán, A., García-Sánchez, V., Esteve, M., Cabriada, J. L., McNicholl, A. G., Pajares, R., Casellas, F., Merino, O., Carpio, D., Vera, M. I., Muñoz, C., Benito, L. M., Bujanda, L., García-Fernández, F. J., Ricart, E., Ginard, D., Velasco, M., Carneros, J. A., Manceñido, N., Calvo, M., Algaba, A., Froilan, C., Cara, C., Maté, J., Abreu, L., and Gisbert, J. P.

Published
2011
Full Text
View/download PDF

20. P545 Deep remission assessed by endoscopy, magnetic resonance or intestinal ultrasound, in refractory Crohn’s disease patients in clinical remission with ustekinumab: a real-life single-centre experience

Author

Calvo Moya, M I, primary, Omella Usieto, I, additional, González Lama, Y, additional, Matallana Royo, V, additional, González Partida, I, additional, Menchen Viso, B, additional, De Lucas Téllez de Meneses, R, additional, González Rodriguez, M, additional, Bella del Castillo, P, additional, and Vera Mendoza, M I, additional

Published
2020
Full Text
View/download PDF

21. P378 Mucosal healing is achieved in most of the inflammatory bowel disease patients in clinical remission with vedolizumab: a real-life single-centre experience

Author

Calvo Moya, M I, primary, Omella Usieto, I, additional, Vera Mendoza, M I, additional, Matallana Royo, V, additional, Gonzalez Partida, I, additional, Manso Manrique, M, additional, Menchén Viso, B, additional, De Lucas Téllez de Meneses, R, additional, González Rodriguez, M, additional, Bella del Castillo, P, additional, and González Lama, Y, additional

Published
2020
Full Text
View/download PDF

22. DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study

Author

Kopylov, U, primary, Hanzel, J, additional, Liefferinckx, C, additional, De Marco, D, additional, Imperatore, N, additional, Plevris, N, additional, Baston-Rey, I, additional, Harris, R, additional, Truyens, M, additional, Domislovic, V, additional, Vavricka, S, additional, Biemans, V, additional, Myers, S, additional, Shaji, S, additional, Ben-Horin, S, additional, González Lama, Y, additional, Gilletta, C, additional, Bar-Gil Shitrit, A, additional, Zelinkova, Z, additional, Weishof, R, additional, Storan, D, additional, Zittan, E, additional, Franchimont, D, additional, Cremer, A, additional, Afif, W, additional, Castiglione, F, additional, Lees, C, additional, Barrero de Acosta, M, additional, Lobaton, T, additional, Doherty, G, additional, Krznaric, Z, additional, Pierik, M, additional, Hoentjen, F, additional, and Drobne, D, additional

Published
2020
Full Text
View/download PDF

23. P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study

Author

Chaparro, M, primary, Sulleiro, S, additional, Bastón-Rey, I, additional, Rodríguez, C, additional, García-Tercero, I, additional, Ramírez, P, additional, García-López, S, additional, Rojas-Feria, M, additional, Gutiérrez, A, additional, Huguet Malavés, J M, additional, García-Sepulcre, M F, additional, Sicilia, B, additional, Bermejo, F, additional, Rodríguez-Moranta, F, additional, Argüelles, F, additional, Marín, I, additional, Leo, E, additional, Arroyo, M, additional, García, M J, additional, Vázquez, J M, additional, Ginard, D, additional, Martínez Cadilla, J, additional, Rubín de Célix, C, additional, García-Herola, A, additional, Hernández-Camba, A, additional, Martín-Arranz, M D, additional, Riestra, S, additional, Varela, P, additional, Velayos, B, additional, Busquets, D, additional, Dueñas, C, additional, Fernández-Salgado, E, additional, Martínez-Montiel, P, additional, Diz-Lois, M T, additional, González-Lama, Y, additional, Muñagorri, A, additional, Navarro-Llavat, M, additional, Guisado, C, additional, Barreiro-de Acosta, M, additional, and Gisbert, J P, additional

Published
2020
Full Text
View/download PDF

24. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy

Author

Hedin, C.R.H. Vavricka, S.R. Stagg, A.J. Schoepfer, A. Raine, T. Puig, L. Pleyer, U. Navarini, A. Van Der Meulen-De Jong, A.E. Maul, J. Katsanos, K. Kagramanova, A. Greuter, T. González-Lama, Y. Van Gaalen, F. Ellul, P. Burisch, J. Bettenworth, D. Becker, M.D. Bamias, G. Rieder, F.

Subjects
education
Abstract

This article reports on the sixth scientific workshop of the European Crohn's and Colitis Organisation [ECCO] on the pathogenesis of extraintestinal manifestations [EIMs] in inflammatory bowel disease [IBD]. This paper has been drafted by 15 ECCO members and 6 external experts [in rheumatology, dermatology, ophthalmology, and immunology] from 10 European countries and the USA. Within the workshop, contributors formed subgroups to address specific areas. Following a comprehensive literature search, the supporting text was finalized under the leadership of the heads of the working groups before being integrated by the group consensus leaders. Copyright © 2018 European Crohn's and Colitis Organisation (ECCO).

Published
2019

26. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy

Author

Hedin, C R H, Vavricka, S R, Stagg, A J, Schoepfer, A, Raine, T, Puig, L, Pleyer, U, Navarini, A, van der Meulen-de Jong, A E, Maul, J, Katsanos, K, Kagramanova, A, Greuter, T, González-Lama, Y, van Gaalen, F, Ellul, P, Burisch, J, Bettenworth, D, Becker, M D, Bamias, G, Rieder, F, Hedin, C R H, Vavricka, S R, Stagg, A J, Schoepfer, A, Raine, T, Puig, L, Pleyer, U, Navarini, A, van der Meulen-de Jong, A E, Maul, J, Katsanos, K, Kagramanova, A, Greuter, T, González-Lama, Y, van Gaalen, F, Ellul, P, Burisch, J, Bettenworth, D, Becker, M D, Bamias, G, and Rieder, F

Abstract

This article reports on the sixth scientific workshop of the European Crohn's and Colitis Organisation [ECCO] on the pathogenesis of extraintestinal manifestations [EIMs] in inflammatory bowel disease [IBD]. This paper has been drafted by 15 ECCO members and 6 external experts [in rheumatology, dermatology, ophthalmology, and immunology] from 10 European countries and the USA. Within the workshop, contributors formed subgroups to address specific areas. Following a comprehensive literature search, the supporting text was finalized under the leadership of the heads of the working groups before being integrated by the group consensus leaders.

Published
2019

29. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

Author

Chaparro, María, primary, Donday, María G., additional, Barreiro-de Acosta, Manuel, additional, Domènech, Eugeni, additional, Esteve, María, additional, García-Sánchez, Valle, additional, Nos, Pilar, additional, Panés, Julián, additional, Martínez, Concepción, additional, Gisbert, Javier P., additional, Abad, F., additional, Aguas Peris, M., additional, Agüero Tejado, E., additional, Alba, C., additional, Albert, M., additional, Alemán, H., additional, Algaba, A., additional, Alonso Abreu, I., additional, Amador, M.P., additional, Amat, M., additional, Angueira, T., additional, Arajol, C., additional, Arias-González, L., additional, Arrondo Velasco, A., additional, Baldán, M., additional, Bardán García, B., additional, Bargalló García, A., additional, Barreiro de Acosta, M., additional, Barrio Andrés, J., additional, Bastida Paz, G., additional, Bastón Rey, I., additional, Batista, L., additional, Bellver Martínez, M., additional, Beltrán Niclós, B., additional, Benítez, J.M., additional, Ber Nieto, Y., additional, Bermejo, F., additional, Bernardo, D., additional, Blázquez Gómez, I., additional, Bouhmidi Assakali, A., additional, Busquets Casals, D., additional, Cabriada Nuño, J.L., additional, Calvet Calvo, X., additional, Calvo Hernández, M.V., additional, Calvo, M., additional, Camps, B., additional, Carbajo, A.Y., additional, Cardona Peitx, G., additional, Caro-Patón, T., additional, Carrillo Palau, M., additional, Carrión Bolorino, S., additional, Casanova, M.J., additional, Casellas Valdé, J.A., additional, Castaño García, A., additional, Castro Senosiain, B., additional, Ceballos, D., additional, Cerrillo, E., additional, Chacón Martínez, S., additional, Consuelo Cañete Pizarro, F., additional, de Castro Parga, M.L., additional, de Miguel, M., additional, de Francisco García, R., additional, de la Cruz Ramírez, M.D., additional, del Hoyo Francisco, J., additional, Delgado Guillena, P., additional, Desongles Corrales, T., additional, Echarri Piudo, A., additional, Espino Paisan, E., additional, Espona Quer, M., additional, Fernández Pordomingo, A., additional, Fernández Forcelledo, J.L., additional, Fernández-Tomé, S., additional, Ferreiro Iglesias, R., additional, Ferrer Bradley, I., additional, Ferrer, A., additional, Figueroa, A., additional, Gallach Montero, M., additional, García Iglesias, P., additional, García García-Lezcún, C., additional, García Ramírez, L., additional, García García, M.J., additional, García-Bosh, O., additional, Garre, A., additional, Giménez Poderós, T., additional, Gómez Irwin, L., additional, Gómez Pastrana, B., additional, Gómez Delgado, E., additional, González Lama, Y., additional, Gracia García, Á., additional, Gracia García, B., additional, Guardiola, J., additional, Guerra, I., additional, Guerra, E., additional, Guillot, V., additional, Gustmancher Saiz, S., additional, Gutiérrez Casbas, A., additional, Hernández Ramírez, V., additional, Hernando Verdugo, M.M., additional, Hernández Muniesa, B., additional, Hernanz Chaves, R., additional, Herrera Justiniano, J.M., additional, Hinojosa del Val, J, additional, Ibáñez Feijoo, S, additional, Iborra Colomino, M, additional, Iglesias Flores, E, additional, Izquierdo García, E., additional, Sampedro González, M J, additional, Lucendo, A J., additional, Jiménez García, N, additional, Leo Carnerero, E., additional, Loizaga Díaz, I., additional, López de Torre Querejazu, A, additional, López Sánchez, P, additional, Luis Parras, J, additional, Maia Boscá, M, additional, Mañosa, M, additional, Marín Pedrosa, S, additional, Marín, A, additional, Marinero, Á, additional, Marín-Jiménez, I, additional, Márquez Mosquera, L, additional, Márquez Galán, JL, additional, Martín Arranz, E, additional, Martín Arranz, MD, additional, Martínez Cadilla, J, additional, Martínez Sesmero, JM, additional, Martínez Sánchez, B, additional, Matallana, V, additional, Mateos Hernández, MI, additional, McNicholl, AG, additional, Mejuto Fernández, R, additional, Melcarne, L, additional, Menchén, L, additional, Méndez-Castrillón Rodríguez, J, additional, Merino Ochoa, O, additional, Mínguez, M, additional, Molas Ferrer, G, additional, Montoro Huguet, M, additional, Montserrat Torres, A, additional, Mora, F, additional, Moraleja Yudego, I, additional, Morales Alvarado, VJ, additional, Morales Martínez, L, additional, Morell, A, additional, Motos García, C, additional, Muñoz Alonso, F, additional, Muñoz Villafranca, MC, additional, Muñoz, JE, additional, Mur, A, additional, Nantes, Ó, additional, Navarro, P, additional, Navarro- Llavat, M, additional, Nos Mateu, P, additional, Núñez Alonso, A, additional, Núñez Ortiz, A, additional, Olivares, D, additional, Ollero Pena, V, additional, Orobitg, J, additional, Ortega, L, additional, Ortiz de Zárate, J, additional, Pallarés Manrique, H, additional, Paradela Carreiro, A, additional, Peral Ballester, L, additional, Pereira Bueno, S, additional, Pérez Martínez, I, additional, Pineda Mariño, JR, additional, Piñero Pérez, C, additional, Planas Giner, A, additional, Plaza Santos, MR, additional, Ponferrada Díaz, Á, additional, Poza Cardón, J, additional, Prieto Vicente, V, additional, Puchades, L, additional, Ramos López, L, additional, Redondo, S, additional, Riestra Menéndez, S, additional, Rivero Tirado, M, additional, Rodríguez Lago, I, additional, Rodríguez Gutiérrez, C, additional, Rodríguez, E, additional, Romero Izquierdo, S, additional, Rubio Iturria, S, additional, Ruiz Antorán, MB, additional, Ruiz, A, additional, Salazar, LF, additional, Sánchez Ulayar, A, additional, Sánchez Gómez, E, additional, Sánchez, C, additional, Sangrador, C, additional, Serra, K, additional, Spicakova, K, additional, Suárez Ferrer, C, additional, Talavera Fabuel, A, additional, Taxonera, C, additional, Tordera, M, additional, Torrella Cortés, E, additional, Tosca, J, additional, Trigo Salado, C, additional, Uriarte Estefanía, F, additional, Van Domselaar, M, additional, Vázquez Morón, JM, additional, Ventura López, P, additional, Vera, M, additional, Vicuña Arregui, M, additional, Villoria Ferrer, A, additional, Virgós Aller, T, additional, and Yáñez Feria, D, additional

Published
2019
Full Text
View/download PDF

30. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

Author

Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, and Gisbert JP

Subjects
Male, Constriction, Pathologic, Inflammatory bowel disease, Gastroenterology, Deprescriptions, 0302 clinical medicine, Crohn Disease, Recurrence, Risk Factors, Medicine, Young adult, Mesalamine, Aged, 80 and over, Incidence, Incidence (epidemiology), Remission Induction, Age Factors, Middle Aged, Antirheumatic Agents, 030220 oncology & carcinogenesis, Retreatment, Disease Progression, Female, 030211 gastroenterology & hepatology, Tumor necrosis factor alpha, Adult, medicine.medical_specialty, Adolescent, Drug-Related Side Effects and Adverse Reactions, Colon, Young Adult, 03 medical and health sciences, Ileum, Internal medicine, Humans, Immunologic Factors, Colitis, Aged, Proportional Hazards Models, Retrospective Studies, Hepatology, Tumor Necrosis Factor-alpha, business.industry, Proportional hazards model, Adalimumab, Retrospective cohort study, Protective Factors, Inflammatory Bowel Diseases, medicine.disease, Infliximab, Discontinuation, Methotrexate, Colitis, Ulcerative, business, Follow-Up Studies
Abstract

OBJECTIVES: The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed. METHODS: This was a retrospective, observational, multicenter study. IBD patients who had been treated with anti-TNFs and in whom these drugs were discontinued after clinical remission was achieved were included. RESULTS: A total of 1,055 patients were included. The incidence rate of relapse was 19% and 17% per patient-year in Crohn's disease and ulcerative colitis patients, respectively. In both Crohn's disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year. The treatment with adalimumab vs. infliximab (hazard ratio (HR)=1.29; 95% confi dence interval (CI)= 1.01-1.66), elective discontinuation of anti-TNFs (HR=1.90; 95% CI= 1.07-3.37) or discontinuation because of adverse events (HR= 2.33; 95% CI= 1.27-2.02) vs. a top-down strategy, colonic localization (HR= 1.51; 95% CI= 1.13-2.02) vs. ileal, and stricturing behavior (HR= 1.5; 95% CI= 1.09-2.05) vs. inflammatory were associated with a higher risk of relapse in Crohn's disease patients, whereas treatment with immunomodulators after discontinuation (HR= 0.67; 95% CI= 0.51-0.87) and age (HR= 0.98; 95% CI= 0.97-0.99) were protective factors. None of the factors were predictive in ulcerative colitis patients. Retreatment of relapse with the same anti-TNF was effective (80% responded) and safe. CONCLUSIONS: The incidence rate of infl ammatory bowel disease relapse after anti-TNF discontinuation is relevant. Some predictive factors of relapse after anti-TNF withdrawal have been identifi ed. Retreatment with the same anti-TNF drug was effective and safe.

Published
2017

31. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy

Author

Hedin, C R H, primary, Vavricka, S R, additional, Stagg, A J, additional, Schoepfer, A, additional, Raine, T, additional, Puig, L, additional, Pleyer, U, additional, Navarini, A, additional, van der Meulen-de Jong, A E, additional, Maul, J, additional, Katsanos, K, additional, Kagramanova, A, additional, Greuter, T, additional, González-Lama, Y, additional, van Gaalen, F, additional, Ellul, P, additional, Burisch, J, additional, Bettenworth, D, additional, Becker, M D, additional, Bamias, G, additional, and Rieder, F, additional

Published
2018
Full Text
View/download PDF

32. AB0876 Correlation between faecal calprotectin levels and tobacco use in patients with spondyloarthritis and without previous diagnosis of inflammatory bowel disease

Author

Espinosa Malpartida, M., primary, Ramos Giráldez, C., additional, Merino Argumánez, C., additional, Ruiz-Antorán, M.B., additional, Campos Esteban, J., additional, Barbadillo Mateos, C., additional, Godoy Tundidor, H., additional, Agudo Castillo, B., additional, González Lama, Y., additional, Andreu Sánchez, J.L., additional, and Sanz Sanz, J., additional

Published
2018
Full Text
View/download PDF

33. FRI0190 Relationship between faecal calprotectin, hlab-27 and acute phase reactants in patients with spondyloarthritis without prior diagnosis of inflammatory bowel disease

Author

Ramos Giraldez, C., primary, Espinosa Malpartida, M., additional, Merino Argumánez, C., additional, Ruíz Antorán, B., additional, Campos Esteban, J., additional, Barbadillo Mateos, C., additional, Godoy Tundidor, H., additional, Agudo Castillo, B., additional, González Lama, Y., additional, Andréu Sánchez, J.L., additional, and Sanz Sanz, J., additional

Published
2018
Full Text
View/download PDF

36. Metástasis gástrica de un adenocarcinoma renal: Hipótesis patogénica y revisión de la literatura

Author

Suárez Fonseca, C., Carballido Rodríguez, J., González Lama, Y., Sola Galarza, I., Rodríguez Reina, G., and Salas Antón, C.

Subjects
Pathogeny, Gastric metastasis, Adenocarcinoma renal, Metástasis gástrica, Patogenia, Renal adenocarcinoma
Abstract

Los tumores gástricos secundarios constituyen una entidad clínica poco habitual, más aún si la localización del tumor primitivo es el riñón. Hasta la actualidad tan solo se han descrito 11 casos diagnosticados en vida. Se presenta un caso clínico de una mujer que presentó una hemorragia digestiva alta secundaria a la presencia de una metástasis gástrica de carcinoma de células renales cuatro años después de la nefrectomía radical. Se realiza una revisión bibliográfica de los casos descritos hasta la fecha en pacientes vivos y se establece una hipótesis patogénica de acuerdo a las teóricas rutas de diseminación para los casos de localización metastática gástrica. Secondary gastric tumours are very uncommon clinical entities and even more so when the site for the primary tumour is the kidney. Only 11 cases of life diagnosis have been described up to now. Contribution of one case report: a female patient presenting with upper GI tract haemorrhage secondary to gastric metastasis from renal cell carcinoma four years after radical nephrectomy. A literature review is made on the cases described up to date in living patients and a pathogenic hypothesis established based on the theoretical dissemination routes for the cases of gastric location of the metastasis.

Published
2004

37. Hepatopatía crónica asociada a fibrosis quística: gasto energético en reposo, factores de riesgo y repercusión en la evolución de la enfermedad

Author

Tabernero da Veiga, S., González Lama, Y., Lama More, R., Martínez Carrasco, M. C., Antelo Landeria, M. C., and Jara Vega, P.

Subjects
Fibrosis quística, Hepatopatía crónica, Gasto energético en reposo, Energy expenditure at rest, Chronic liver disease, Cystic fibrosis
Abstract

Introducción y objetivos: La fibrosis quística es la enfermedad recesiva más frecuente. Existen diferentes alteraciones hepatobiliares; la más importante es el desarrollo de obstrucción biliar y fibrosis periportal. El objetivo es valorar la influencia de la hepatopatía en el estado nutricional, la evolución de la enfermedad y los factores de riesgo asociados. Ámbito: Unidad de Nutrición del Servicio de Gastroenterología del Hospital Infantil La Paz. Material y métodos: Estudio longitudinal prospectivo con 53 pacientes valorados en tres momentos durante 3 años; al inicio, al año y a los 3 años. Solo 37 se siguieron los 3 años. Se realizan 111 mediciones que incluyen: análisis de la composición corporal, del gasto energético, de la ingesta y de las pérdidas energéticas así como balance nitrogenado. Simultáneamente se realizan pruebas de función respiratoria y se valora la presencia de reagudización respiratoria. Resultados: 37 pacientes, 19 mujeres y 18 varones (edad media 13,04 años ± 3,28). Doce (32,43%) fueron diagnosticados de hepatopatía (edad media 12,16 años ± 3,86 DS, 11 varones, 1 mujer) de los cuales 1 presentó íleo meconial, 5 eran homocigotos, 5 heterocigotos y los 2 restantes presentaban otras mutaciones. Los hepatópatas presentan parámetros antropométricos mejores o similares que los pacientes sin hepatopatía (p NS). Media del índice de Waterlow en hepatópatas: 93,62% ± 7,87 DS; no hepatópatas: 93,06% ± 10,97 DS (p NS). Media de FEV1 en hepatópatas: 88,81 ± 27,32 DS; no hepatópatas: 75,21 ± 27,92 DS (p

Published
2004

38. Hepatopatía crónica asociada a fibrosis quística: gasto energético en reposo, factores de riesgo y repercusión en la evolución de la enfermedad

Author

Tabernero da Veiga,S., González Lama,Y., Lama More,R., Martínez Carrasco,M. C., Antelo Landeria,M. C., and Jara Vega,P.

Subjects
Fibrosis quística, Hepatopatía crónica, Gasto energético en reposo
Abstract

Introducción y objetivos: La fibrosis quística es la enfermedad recesiva más frecuente. Existen diferentes alteraciones hepatobiliares; la más importante es el desarrollo de obstrucción biliar y fibrosis periportal. El objetivo es valorar la influencia de la hepatopatía en el estado nutricional, la evolución de la enfermedad y los factores de riesgo asociados. Ámbito: Unidad de Nutrición del Servicio de Gastroenterología del Hospital Infantil La Paz. Material y métodos: Estudio longitudinal prospectivo con 53 pacientes valorados en tres momentos durante 3 años; al inicio, al año y a los 3 años. Solo 37 se siguieron los 3 años. Se realizan 111 mediciones que incluyen: análisis de la composición corporal, del gasto energético, de la ingesta y de las pérdidas energéticas así como balance nitrogenado. Simultáneamente se realizan pruebas de función respiratoria y se valora la presencia de reagudización respiratoria. Resultados: 37 pacientes, 19 mujeres y 18 varones (edad media 13,04 años ± 3,28). Doce (32,43%) fueron diagnosticados de hepatopatía (edad media 12,16 años ± 3,86 DS, 11 varones, 1 mujer) de los cuales 1 presentó íleo meconial, 5 eran homocigotos, 5 heterocigotos y los 2 restantes presentaban otras mutaciones. Los hepatópatas presentan parámetros antropométricos mejores o similares que los pacientes sin hepatopatía (p NS). Media del índice de Waterlow en hepatópatas: 93,62% ± 7,87 DS; no hepatópatas: 93,06% ± 10,97 DS (p NS). Media de FEV1 en hepatópatas: 88,81 ± 27,32 DS; no hepatópatas: 75,21 ± 27,92 DS (p

Published
2004

39. P216 Inflammatory bowel disease unclassified (IBDU) in real practice: prevalence, clinical course and therapy requirements

Author

Bermejo, F., primary, Algaba, A., additional, Cuño, J.L., additional, Botella, B., additional, Taxonera, C., additional, Calvo, M., additional, López-Serrano, P., additional, Ballesteros, L., additional, Chaparro, M., additional, Ponferrada, A., additional, Manceñido, N., additional, de-la-Poza, G., additional, López-San Román, A., additional, Martin, D., additional, Olivares, D., additional, González-Lama, Y., additional, Pérez-Calle, J.L., additional, Gómez, G., additional, Gisbert, J.P., additional, and Guerra, I., additional

Published
2013
Full Text
View/download PDF

40. TRATAMIENTO DE LA ANEMIA FERROPÉNICA CON HIERRO (FE) ORAL E INTRAVENOSO (IV) EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL (EII)

Author

Gisbert, J.P., primary, Bermejo, F., additional, Pajares, R., additional, Pérez-Calle, J.L., additional, Rodríguez, M., additional, Algaba, A., additional, Mancenido, N., additional, de la Morena, F., additional, Carneros, J.A., additional, McNicholl, A.G., additional, González-Lama, Y., additional, and Maté, J., additional

Published
2009
Full Text
View/download PDF

41. EFICACIA Y SEGURIDAD DEL METOTREXATO EN LA ENFERMEDAD INFLAMATORIA INTESTINAL: EXPERIENCIA DEL GRUPO DE MADRID

Author

González-Lama, Y., primary, Taxonera, C., additional, López-Sanromán, A., additional, Pérez-Calle, J.L., additional, Bermejo, F., additional, Pajares, R., additional, McNicholl, A.G., additional, Opio, V., additional, Mendoza, J.L., additional, López, P., additional, Algaba, A., additional, Estellés, J., additional, Barbero, A., additional, Mendoza, J., additional, Maté, J., additional, and Gisbert, J.P., additional

Published
2009
Full Text
View/download PDF

42. UTILIDAD DE LA CALPROTECTINA Y LACTOFERRINA FECAL EN LA PREDICCIÓN DE LA RECIDIVA DE LA ENFERMEDAD INFLAMATORIA INTESTINAL (EII)

Author

Gisbert, J.P., primary, Bermejo, F., additional, Pérez-Calle, J.L., additional, Taxonera, C., additional, Vera, I., additional, McNicholl, A.G., additional, Algaba, A., additional, López, P., additional, López-Palacios, N., additional, Calvo, M., additional, González-Lama, Y., additional, Carneros, J.A., additional, Velasco, M., additional, and Maté, J., additional

Published
2009
Full Text
View/download PDF

43. LA DETERMINACIÓN SISTEMÁTICA DE LOS METABOLITOS DE LA AZATIOPRINA DURANTE EL SEGUIMIENTO DE LOS PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL (EII) TRATADOS CON TIOPURÍNICOS NO ES ÚTIL: RESULTADOS FINALES DEL ESTUDIO METAZA

Author

González-Lama, Y., primary, McNicholl, A.G., additional, Bermejo, F., additional, López-Sanromán, A., additional, García, M.V., additional, Esteve, M., additional, Cabriada, J.L., additional, Pajares, R., additional, Casellas, F., additional, Merino, O., additional, Carpio, D., additional, Calvo, M., additional, Muñoz, C., additional, Benito, L.M., additional, Bufanda, L., additional, García-Hernández, F.J., additional, Ricart, E., additional, Ginard, D., additional, Velasco, M., additional, Carneros, J.A., additional, Manceñido, N., additional, Vera, M.I., additional, Algaba, A., additional, Froilan, C., additional, Abreu, L., additional, Maté, J., additional, Cara, C., additional, and Gisbert, J.P., additional

Published
2009
Full Text
View/download PDF

44. ESOFAGITIS EOSINOFÍLICA. UNA PATOLOGÍA PREVALENTE

Author

Pérez Arellano, E., primary, Sosa, G., additional, Revenga, M., additional, Jiménez Heffernan, J.A., additional, Tomas, E., additional, Robles, M.J., additional, González Lama, Y., additional, Tejerina, E., additional, Albillos, A., additional, and De la Morena, E., additional

Published
2009
Full Text
View/download PDF

45. P100 FAECAL CALPROTECTIN'S UTILITY IN THE PREDICTION OF INFLAMMATORY BOWEL DISEASE (IBD) RELAPSES

Author

Gisbert, J.P., primary, Bermejo, F., additional, Pérez-Calle, J., additional, Taxonera, C., additional, Vera, I., additional, González-Lama, Y., additional, Algaba, A., additional, López, P., additional, López-Palacios, N., additional, Calvo, M., additional, McNicholl, A., additional, Carneros, J., additional, Velasco, M., additional, and Maté, J., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results